폐암 진단약 시장, 진단 검사 유형 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)
Lung Cancer Diagnostics Market, Diagnostic Test Type - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1606343
리서치사:Transparency Market Research
발행일:2024년 10월
페이지 정보:영문 228 Pages
라이선스 & 가격 (부가세 별도)
한글목차
폐암 진단약 시장 - 조사 범위
TMR의 조사 리포트 '세계의 폐암 진단약 시장'은 2024-2034년의 예측 기간에 시장의 지표에 관한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회에 대해서도 조사하고 있습니다. 2024년을 기준년, 2034년을 예측년으로 2018-2034년의 세계 폐암 진단약 시장의 매출과 예측을 제공하고 있습니다. 또한 2024-2034년의 세계 폐암 진단약 시장의 연평균 성장률(CAGR %)도 게재하고 있습니다.
본 리포트는 광범위한 조사를 거쳐 작성되고 있습니다. 1차 조사에서는 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 메이커에 대한 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 애뉴얼 리포트, 프레스 릴리스, 관련 자료 등을 참조하여 폐암 진단약 시장을 추측했습니다.
시장 스냅숏
2023년 시장 규모
151억 달러
2034년 시장 규모
348억 달러
CAGR
7.9%
본 리포트에서는 세계의 폐암 진단약 시장의 경쟁 구도에 대해 심층 분석하고 있습니다. 세계의 폐암 진단약 시장에서 사업을 운영하는 주요 기업이 식별되고, 각 기업이 다양한 속성으로 프로파일링되고 있습니다. 기업 개요, 재무 상황, 최근 동향, SWOT 등이 본 리포트에서 소개하고 있는 세계의 폐암 진단약 시장에서 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 개요 : 세계 시장
제4장 시장 개요
서론
개요
시장 역학
세계의 시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
산업계에서 최근 기술 진보
폐암 진단 툴로서의 액체생검의 출현에 관한 인사이트
가격 동향
주요 지역/국에서 규제 상황
Porter's Five Forces 분석
PESTEL 분석
밸류체인 분석
신규 참여자를 위한 시장 개척 전략
최종사용자의 주요 구입 지표
주요 업계 이벤트(파트너십, 협업, 제품 승인, 합병과 인수, 자금조달과 투자)
경쟁이 제공하는 제품의 벤치마킹
제6장 세계 시장 분석과 예측 : 진단 테스트 유형별
서론과 정의
주요 조사 결과/ 진전
시장 금액 예측 : 진단 테스트 유형별, 2020-2034년
생검
침생검
경기관지 생검
흉강경하 생검
액체생검
순환종양세포(CTC)
순환 종양 DNA
유리 RNA(cfRNA)
엑소좀
프로테옴 해석
기타
영상 검사
자기공명영상(MRI)
컴퓨터 단층촬영(CT) 스캔
흉부 초음파 검사
양전자 방출 단층촬영(PET)
기타 영상 검사
분자 검사
기타
진단 테스트 유형별 시장의 매력
제7장 세계 시장 분석과 예측 : 제품 유형별
서론과 정의
주요 조사 결과/ 진전
시장 금액 예측 : 제품 유형별, 2020-2034년
기기
소모품
제품 유형별 시장의 매력
제8장 세계 시장 분석과 예측 : 암 유형별
서론과 정의
주요 조사 결과/ 진전
시장 금액 예측 : 암 유형별, 2020-2034년
비소세포 폐암(NSCLC)
소세포 폐암(SCLC)
암 유형별 시장의 매력
제9장 세계 시장 분석과 예측 : 최종사용자별
서론과 정의
주요 조사 결과/ 진전
시장 금액 예측 : 최종사용자별, 2020-2034년
병원
클리닉
진단·영상 진단 센터
암조사기관
최종사용자별 시장의 매력
제10장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
지역별 시장의 매력
제11장 북미의 시장 분석과 예측
미국
캐나다
제12장 유럽의 시장 분석과 예측
독일
영국
프랑스
스페인
이탈리아
기타 유럽 지역
제13장 아시아태평양의 시장 분석과 예측
중국
일본
인도
호주와 뉴질랜드
기타 아시아태평양
제14장 라틴아메리카의 시장 분석과 예측
브라질
멕시코
기타 라틴아메리카 지역
제15장 중동 및 아프리카의 시장 분석과 예측
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
제16장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업 계층과 규모별)
시장 점유율 분석 기업별(2023년)
기업 개요
Abbott
Siemens Healthcare
GE Healthcare
Amoy Diagnostics Co.
Boditech Med, Inc.
Danaher
F. Hoffmann-La Roche
INOVIQ
MedGenome
Quest Diagnostics Incorporated
DiaSorin S.p.A.
Oncocyte Corporation
QIAGEN
Thermo Fisher Scientific, Inc.
NanoString Technologies
Biodesix
Other Prominent Players
KSA
영문 목차
영문목차
Lung Cancer Diagnostics Market - Scope of Report
TMR's report on the global lung cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global lung cancer diagnostics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung cancer diagnostics market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lung cancer diagnostics market.
Market Snapshot
Market Value in 2023
US$ 15.1 Bn
Market Value in 2034
US$ 34.8 Bn
CAGR
7.9%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lung cancer diagnostics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lung cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lung cancer diagnostics market.
The report delves into the competitive landscape of the global lung cancer diagnostics market. Key players operating in the global lung cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lung cancer diagnostics market profiled in this report.
Key Questions Answered in Global lung cancer diagnostics Market Report:
What is the sales/revenue generated by lung cancer diagnostics across all regions during the forecast period?
What are the opportunities in the global lung cancer diagnostics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Lung Cancer Diagnostics Market - Research Objectives and Research Approach
The comprehensive report on the global lung cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global lung cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lung cancer diagnostics market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Lung Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lung Cancer Diagnostics Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Recent Technological Advancements in Lung Cancer Diagnostics Industry
5.2. Insights on Emergence of Liquid Biopsy as a Lung Cancer Diagnostic Tool
5.3. Lung Cancer Diagnostics Pricing Trends
5.4. Regulatory Landscape across Key Regions / Countries
5.5. PORTER's Five Forces Analysis
5.6. PESTEL Analysis
5.7. Value Chain Analysis
5.8. Go-To Market Strategy for New Entrants
5.9. Key Purchase Metrics for End-users
5.10. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions, funding and investments)
5.11. Benchmarking of the Products Offered by the Competitors
6. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Diagnostic Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Diagnostic Test Type, 2020-2034
6.3.1. Biopsy
6.3.1.1. Needle biopsy
6.3.1.2. Transbronchial biopsy
6.3.1.3. Thoracoscopic biopsy
6.3.1.4. Liquid Biopsy
6.3.1.4.1. Circulating Tumor Cells (CTCs)
6.3.1.4.2. Circulating Tumor DNA
6.3.1.4.3. Cell-Free RNA (cfRNA)
6.3.1.4.4. Exosomes
6.3.1.4.5. Proteomic Analysis
6.3.1.5. Others
6.3.2. Imaging Tests
6.3.2.1. Magnetic Resonance Imaging (MRI)
6.3.2.2. Computed Tomography (CT) Scan
6.3.2.3. Chest Ultrasound
6.3.2.4. Positron Emission Tomography (PET)
6.3.2.5. Other Imaging Tests
6.3.3. Molecular Testing
6.3.4. Others
6.4. Market Attractiveness By Diagnostic Test Type
7. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Product Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Product Type, 2020-2034
7.3.1. Instruments
7.3.2. Consumables
7.4. Market Attractiveness By Product Type
8. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Cancer Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Cancer Type, 2020-2034
8.3.1. Non-small cell lung cancer (NSCLC)
8.3.2. Small cell lung cancer (SCLC)
8.4. Market Attractiveness By Cancer Type
9. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By End-user, 2020-2034
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Diagnostic & Imaging Centers
9.3.4. Cancer Research Institutes
9.4. Market Attractiveness By End-user
10. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Lung Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
11.2.1. Biopsy
11.2.1.1. Needle biopsy
11.2.1.2. Transbronchial biopsy
11.2.1.3. Thoracoscopic biopsy
11.2.1.4. Liquid Biopsy
11.2.1.4.1. Circulating Tumor Cells (CTCs)
11.2.1.4.2. Circulating Tumor DNA
11.2.1.4.3. Cell-Free RNA (cfRNA)
11.2.1.4.4. Exosomes
11.2.1.4.5. Proteomic Analysis
11.2.1.5. Others
11.2.2. Imaging Tests
11.2.2.1. Magnetic Resonance Imaging (MRI)
11.2.2.2. Computed Tomography (CT) Scan
11.2.2.3. Chest Ultrasound
11.2.2.4. Positron Emission Tomography (PET)
11.2.2.5. Other Imaging Tests
11.2.3. Molecular Testing
11.2.4. Others
11.3. Market Value Forecast By Product Type, 2020-2034
11.3.1. Instruments
11.3.2. Consumables
11.4. Market Value Forecast By Cancer Type, 2020-2034
11.4.1. Non-small cell lung cancer (NSCLC)
11.4.2. Small cell lung cancer (SCLC)
11.5. Market Value Forecast By End-user, 2020-2034
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Diagnostic & Imaging Centers
11.5.4. Cancer Research Institutes
11.6. Market Value Forecast By Country, 2020-2034
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Diagnostic Test Type
11.7.2. By Product Type
11.7.3. By Cancer Type
11.7.4. By End-user
11.7.5. By Country
12. Europe Lung Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
12.2.1. Biopsy
12.2.1.1. Needle biopsy
12.2.1.2. Transbronchial biopsy
12.2.1.3. Thoracoscopic biopsy
12.2.1.4. Liquid Biopsy
12.2.1.4.1. Circulating Tumor Cells (CTCs)
12.2.1.4.2. Circulating Tumor DNA
12.2.1.4.3. Cell-Free RNA (cfRNA)
12.2.1.4.4. Exosomes
12.2.1.4.5. Proteomic Analysis
12.2.1.5. Others
12.2.2. Imaging Tests
12.2.2.1. Magnetic Resonance Imaging (MRI)
12.2.2.2. Computed Tomography (CT) Scan
12.2.2.3. Chest Ultrasound
12.2.2.4. Positron Emission Tomography (PET)
12.2.2.5. Other Imaging Tests
12.2.3. Molecular Testing
12.2.4. Others
12.3. Market Value Forecast By Product Type, 2020-2034
12.3.1. Instruments
12.3.2. Consumables
12.4. Market Value Forecast By Cancer Type, 2020-2034
12.4.1. Non-small cell lung cancer (NSCLC)
12.4.2. Small cell lung cancer (SCLC)
12.5. Market Value Forecast By End-user, 2020-2034
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Diagnostic & Imaging Centers
12.5.4. Cancer Research Institutes
12.6. Market Value Forecast By Country / Sub-region, 2020-2034
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Diagnostic Test Type
12.7.2. By Product Type
12.7.3. By Cancer Type
12.7.4. By End-user
12.7.5. By Country / Sub-region
13. Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
13.2.1. Biopsy
13.2.1.1. Needle biopsy
13.2.1.2. Transbronchial biopsy
13.2.1.3. Thoracoscopic biopsy
13.2.1.4. Liquid Biopsy
13.2.1.4.1. Circulating Tumor Cells (CTCs)
13.2.1.4.2. Circulating Tumor DNA
13.2.1.4.3. Cell-Free RNA (cfRNA)
13.2.1.4.4. Exosomes
13.2.1.4.5. Proteomic Analysis
13.2.1.5. Others
13.2.2. Imaging Tests
13.2.2.1. Magnetic Resonance Imaging (MRI)
13.2.2.2. Computed Tomography (CT) Scan
13.2.2.3. Chest Ultrasound
13.2.2.4. Positron Emission Tomography (PET)
13.2.2.5. Other Imaging Tests
13.2.3. Molecular Testing
13.2.4. Others
13.3. Market Value Forecast By Product Type, 2020-2034
13.3.1. Instruments
13.3.2. Consumables
13.4. Market Value Forecast By Cancer Type, 2020-2034
13.4.1. Non-small cell lung cancer (NSCLC)
13.4.2. Small cell lung cancer (SCLC)
13.5. Market Value Forecast By End-user, 2020-2034
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Diagnostic & Imaging Centers
13.5.4. Cancer Research Institutes
13.6. Market Value Forecast By Country / Sub-region, 2020-2034
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Diagnostic Test Type
13.7.2. By Product Type
13.7.3. By Cancer Type
13.7.4. By End-user
13.7.5. By Country / Sub-region
14. Latin America Lung Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
14.2.1. Biopsy
14.2.1.1. Needle biopsy
14.2.1.2. Transbronchial biopsy
14.2.1.3. Thoracoscopic biopsy
14.2.1.4. Liquid Biopsy
14.2.1.4.1. Circulating Tumor Cells (CTCs)
14.2.1.4.2. Circulating Tumor DNA
14.2.1.4.3. Cell-Free RNA (cfRNA)
14.2.1.4.4. Exosomes
14.2.1.4.5. Proteomic Analysis
14.2.1.5. Others
14.2.2. Imaging Tests
14.2.2.1. Magnetic Resonance Imaging (MRI)
14.2.2.2. Computed Tomography (CT) Scan
14.2.2.3. Chest Ultrasound
14.2.2.4. Positron Emission Tomography (PET)
14.2.2.5. Other Imaging Tests
14.2.3. Molecular Testing
14.2.4. Others
14.3. Market Value Forecast By Product Type, 2020-2034
14.3.1. Instruments
14.3.2. Consumables
14.4. Market Value Forecast By Cancer Type, 2020-2034
14.4.1. Non-small cell lung cancer (NSCLC)
14.4.2. Small cell lung cancer (SCLC)
14.5. Market Value Forecast By End-user, 2020-2034
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Diagnostic & Imaging Centers
14.5.4. Cancer Research Institutes
14.6. Market Value Forecast By Country / Sub-region, 2020-2034
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Diagnostic Test Type
14.7.2. By Product Type
14.7.3. By Cancer Type
14.7.4. By End-user
14.7.5. By Country / Sub-region
15. Middle East & Africa Lung Cancer Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
15.2.1. Biopsy
15.2.1.1. Needle biopsy
15.2.1.2. Transbronchial biopsy
15.2.1.3. Thoracoscopic biopsy
15.2.1.4. Liquid Biopsy
15.2.1.4.1. Circulating Tumor Cells (CTCs)
15.2.1.4.2. Circulating Tumor DNA
15.2.1.4.3. Cell-Free RNA (cfRNA)
15.2.1.4.4. Exosomes
15.2.1.4.5. Proteomic Analysis
15.2.1.5. Others
15.2.2. Imaging Tests
15.2.2.1. Magnetic Resonance Imaging (MRI)
15.2.2.2. Computed Tomography (CT) Scan
15.2.2.3. Chest Ultrasound
15.2.2.4. Positron Emission Tomography (PET)
15.2.2.5. Other Imaging Tests
15.2.3. Molecular Testing
15.2.4. Others
15.3. Market Value Forecast By Product Type, 2020-2034
15.3.1. Instruments
15.3.2. Consumables
15.4. Market Value Forecast By Cancer Type, 2020-2034
15.4.1. Non-small cell lung cancer (NSCLC)
15.4.2. Small cell lung cancer (SCLC)
15.5. Market Value Forecast By End-user, 2020-2034
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Diagnostic & Imaging Centers
15.5.4. Cancer Research Institutes
15.6. Market Value Forecast By Country / Sub-region, 2020-2034
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Diagnostic Test Type
15.7.2. By Product Type
15.7.3. By Cancer Type
15.7.4. By End-user
15.7.5. By Country / Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
